Dr. Erkan Baloglu

Dr. Erkan Baloglu brings over 20 years of hands-on leadership in small molecule drug discovery and early clinical development, with a proven ability to turn first-in-class concepts into clinical-stage therapies.

As the inventor and program lead behind multiple oncology assets—Eltanexor, Padnarsertib, and co-inventor of KPT-350 (acquired by Biogen)—his work has contributed directly to five INDs and one FDA-approved drug (Selinexor/XPOVIO®).

Dr. Baloglu combines deep scientific insight with strategic execution, having advised over 30 biotech and VC-backed companies globally.

His experience spans medicinal chemistry, DMPK, CRO management, and translational strategy